These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 15809016)

  • 1. Progression of diabetic retinopathy during improved metabolic control may be treated with reduced insulin dosage and/or somatostatin analogue administration -- a case report.
    Chantelau E; Frystyk J
    Growth Horm IGF Res; 2005 Apr; 15(2):130-5. PubMed ID: 15809016
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of chronic treatment with octreotide nasal powder on serum levels of growth hormone, insulin-like growth factor I, insulin-like growth factor binding proteins 1 and 3 in acromegalic patients.
    Invitti C; Fatti L; Camboni MG; Porcu L; Danesi L; Delitala G; Cavagnini F
    J Endocrinol Invest; 1996 Sep; 19(8):548-55. PubMed ID: 8905479
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Therapy of diabetic retinopathy with somatostatin analogues].
    Lang GE
    Ophthalmologe; 2004 Mar; 101(3):290-3. PubMed ID: 15007609
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evidence that upregulation of serum IGF-1 concentration can trigger acceleration of diabetic retinopathy.
    Chantelau E
    Br J Ophthalmol; 1998 Jul; 82(7):725-30. PubMed ID: 9924360
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Free and total insulin-like growth factor I (IGF-I), IGF-binding protein-1 (IGFBP-1), and IGFBP-3 and their relationships to the presence of diabetic retinopathy and glomerular hyperfiltration in insulin-dependent diabetes mellitus.
    Janssen JA; Jacobs ML; Derkx FH; Weber RF; van der Lely AJ; Lamberts SW
    J Clin Endocrinol Metab; 1997 Sep; 82(9):2809-15. PubMed ID: 9284701
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of one year continuous subcutaneous infusion of a somatostatin analogue, octreotide, on early retinopathy, metabolic control and thyroid function in Type I (insulin-dependent) diabetes mellitus.
    Kirkegaard C; Nørgaard K; Snorgaard O; Bek T; Larsen M; Lund-Andersen H
    Acta Endocrinol (Copenh); 1990 Jun; 122(6):766-72. PubMed ID: 2197845
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diabetic retinopathy, visual acuity, and medical risk indicators: a continuous 10-year follow-up study in Type 1 diabetic patients under routine care.
    Lövestam-Adrian M; Agardh CD; Torffvit O; Agardh E
    J Diabetes Complications; 2001; 15(6):287-94. PubMed ID: 11711321
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Retinal photocoagulation does not influence intraocular levels of IGF-I, IGF-II and IGF-BP3 in proliferative diabetic retinopathy-evidence for combined treatment of PDR with somatostatin analogues and retinal photocoagulation?
    Spranger J; Möhlig M; Osterhoff M; Bühnen J; Blum WF; Pfeiffer AF
    Horm Metab Res; 2001 May; 33(5):312-6. PubMed ID: 11440279
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of intraperitoneal insulin delivery on growth hormone binding protein, insulin-like growth factor (IGF)-I, and IGF-binding protein-3 in IDDM.
    Hanaire-Broutin H; Sallerin-Caute B; Poncet MF; Tauber M; Bastide R; Chalé JJ; Rosenfeld R; Tauber JP
    Diabetologia; 1996 Dec; 39(12):1498-504. PubMed ID: 8960832
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of modulation of GH/IGF-I axis in the development of diabetic proliferative retinopathy.
    Genovese S; Riccardi G
    J Endocrinol Invest; 2003; 26(8 Suppl):114-6. PubMed ID: 15233225
    [No Abstract]   [Full Text] [Related]  

  • 11. The efficacy of octreotide in the therapy of severe nonproliferative and early proliferative diabetic retinopathy: a randomized controlled study.
    Grant MB; Mames RN; Fitzgerald C; Hazariwala KM; Cooper-DeHoff R; Caballero S; Estes KS
    Diabetes Care; 2000 Apr; 23(4):504-9. PubMed ID: 10857943
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Octreotide (somatostatin analog) treatment reduces endothelial cell dysfunction in patients with diabetes mellitus.
    Clemens A; Klevesath MS; Hofmann M; Raulf F; Henkels M; Amiral J; Seibel MJ; Zimmermann J; Ziegler R; Wahl P; Nawroth PP
    Metabolism; 1999 Oct; 48(10):1236-40. PubMed ID: 10535384
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibitory effects of octreotide on renal and glomerular growth in early experimental diabetes in mice.
    Grønbaek H; Nielsen B; Schrijvers B; Vogel I; Rasch R; Flyvbjerg A
    J Endocrinol; 2002 Mar; 172(3):637-43. PubMed ID: 11874712
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of estradiol and exogenous insulin-like growth factor I (IGF-I) on the IGF-I axis during growth hormone inhibition and antagonism.
    Wilson ME
    J Clin Endocrinol Metab; 1998 Nov; 83(11):4013-21. PubMed ID: 9814485
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Octreotide reduces vitreous hemorrhage and loss of visual acuity risk in patients with high-risk proliferative diabetic retinopathy.
    Boehm BO; Lang GK; Jehle PM; Feldman B; Lang GE
    Horm Metab Res; 2001 May; 33(5):300-6. PubMed ID: 11440277
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The insulin-like growth factor system and Type 1 diabetic retinopathy during pregnancy.
    Loukovaara S; Immonen IJ; Koistinen R; Rutanen EM; Hiilesmaa V; Loukovaara M; Kaaja RJ
    J Diabetes Complications; 2005; 19(5):297-304. PubMed ID: 16112506
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stabilization of severe proliferative diabetic retinopathy by long-term treatment with SMS 201-995.
    Mallet B; Vialettes B; Haroche S; Escoffier P; Gastaut P; Taubert JP; Vague P
    Diabete Metab; 1992; 18(6):438-44. PubMed ID: 1297600
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reversion of 'early worsening' of diabetic retinopathy by deliberate restoration of poor metabolic control.
    Chantelau E; Meyer-Schwickerath R
    Ophthalmologica; 2003; 217(5):373-7. PubMed ID: 12913330
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Insulin-like growth factors and binding proteins in patients with recent-onset type 1 (insulin-dependent) diabetes mellitus: influence of diabetes control and intraportal insulin infusion.
    Shishko PI; Dreval AV; Abugova IA; Zajarny IU; Goncharov VC
    Diabetes Res Clin Pract; 1994 Aug; 25(1):1-12. PubMed ID: 7530621
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Different Effects of Intraperitoneal and Subcutaneous Insulin Administration on the GH-IGF-1 Axis in Type 1 Diabetes.
    van Dijk PR; Logtenberg SJ; Chisalita SI; Hedman CA; Groenier KH; Gans RO; Kleefstra N; Arnqvist HJ; Bilo HJ
    J Clin Endocrinol Metab; 2016 Jun; 101(6):2493-501. PubMed ID: 27115061
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.